Jammal Nadya, Kantarjian Hagop M, Haddad Fadi, Jabbour Elias J
University of Texas, MD Anderson Cancer Center, Houston, Texas.
Clin Adv Hematol Oncol. 2022 Mar;20(3):161-168.
Acute lymphoblastic leukemia, commonly known to affect the younger population, is a disease that is affecting the elderly in an increasing amount as the human life span continues to lengthen. Traditional cytotoxic agents are intolerable to elderly individuals owing to comorbidities, weakened immune systems, and organ dysfunction. Alternative agents and regimens are needed to allow for elderly patient to tolerate full cycles of therapy while providing complete and durable remissions. With the advent of targeted agents, such as monoclonal antibodies and bispecific T-cell engagers, a number of options have proven themselves to be effective in the elderly and optimal for tolerability. Here, we review and discuss the literature addressing regimens that use new agents, such as blinatumomab, inotuzumab ozogamicin, and venetoclax, and those that use modified dosing strategies of traditional chemotherapy.
急性淋巴细胞白血病通常多见于年轻人群，但随着人类寿命的不断延长，该疾病在老年人群中的发病率也日益增加。由于并存疾病、免疫系统衰弱和器官功能障碍，老年个体难以耐受传统的细胞毒性药物。因此，需要替代药物和治疗方案，以使老年患者能够耐受完整疗程的治疗，同时实现完全且持久的缓解。随着单克隆抗体和双特异性T细胞衔接器等靶向药物的出现，一些药物已证明对老年患者有效且耐受性最佳。在此，我们回顾并讨论了有关使用新药物（如博纳吐单抗、奥英妥珠单抗和维奈克拉）的治疗方案以及使用传统化疗改良给药策略的治疗方案的文献。
